Foundayo Shortage: What Providers and Prescribers Need to Know in 2026

Foundayo (orforglipron) received FDA approval on April 1, 2026 — and within hours, prescribers began fielding patient questions and requests. The approval was historic: the first new molecular entity cleared under the FDA's National Priority Voucher program, approved 294 days ahead of the original PDUFA date. But the speed of approval created a challenge that prescribers are now navigating: uneven pharmacy availability in the weeks and months following launch.

This guide is written for healthcare providers — primary care physicians, obesity medicine specialists, endocrinologists, nurse practitioners, and physician assistants — who are prescribing or considering prescribing Foundayo and need to set accurate expectations with patients.

Official Shortage Status as of Mid-2026

Foundayo is not currently listed on the FDA's Drug Shortage Database. This distinguishes it from the Wegovy (semaglutide) shortage of 2022–2024, which was a formal, FDA-designated manufacturing shortage. With Foundayo, the issue is distribution ramp-up: the drug is manufactured in adequate quantities, but retail pharmacy stocking has not yet caught up with demand across all markets.

This is clinically important because it affects how you counsel patients. Unlike a true shortage where patients may need to switch medications indefinitely, Foundayo's availability gap is expected to close as supply chains normalize — likely within the first 3–6 months post-launch.

Why Patients Are Struggling to Fill Their Foundayo Prescriptions

There are several overlapping factors driving availability challenges:

• Accelerated FDA timeline: Foundayo's approval was the fastest NME approval since 2002, coming 294 days before the PDUFA date. This gave the supply chain less preparation time than typical new drug launches.
• Massive unmet demand: Eli Lilly has stated that fewer than 1 in 10 eligible patients currently take a GLP-1 medication. Foundayo targets the large cohort of patients who want treatment but prefer or require an oral option. The addressable patient population is in the tens of millions.
• Telehealth amplification: Multiple telehealth platforms activated Foundayo prescribing on Day 1 of approval. Because no injection training is required (unlike injectables), the frictionless access created an immediate prescription surge that outpaced pharmacy stocking.
• Insurance coverage lag: Major PBMs had not finalized formulary placement at launch. Prior authorization requirements are the norm, and some insurers are still determining their criteria and coverage policies. This creates patient frustration when a prescription is written but either insurance doesn't cover it or the pharmacy doesn't have it.

What to Tell Patients When You Prescribe Foundayo

Setting expectations at the point of prescribing will reduce patient frustration and unnecessary follow-up calls to your office. Consider including these points in patient counseling:

1. Local pharmacy stock is variable. Not every pharmacy has Foundayo yet. The patient may need to call around or use LillyDirect.
2. LillyDirect is the most reliable current source. Advise patients to use LillyDirect (NPI: 1912889320) or Amazon Pharmacy if their local pharmacy is out of stock.
3. Insurance prior auth is likely. Most commercial plans require prior authorization. Proactively submitting PA documentation at the time of prescribing reduces delays.
4. Cost without coverage is manageable. The Lilly self-pay savings card caps cost at $149/month (0.8 mg starter dose) to $299/month (maintenance doses). This is far less than other injectable GLP-1s at list price. LillyDirect pricing is transparent.
5. Medicare coverage is coming. Medicare Part D coverage is expected under the CMS BALANCE Model starting July 1, 2026, at approximately $50/month for eligible enrollees.

Prescribing Considerations: Key Clinical Points for Foundayo

For providers adding Foundayo to their clinical toolkit, several practical considerations are worth noting:

• Contraindications: Do not prescribe in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Foundayo carries a Boxed Warning for thyroid C-cell tumors (class effect).
• Drug interactions to flag: Foundayo is metabolized via CYP3A4. Avoid strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir). Avoid strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Cap Foundayo at 9 mg/day with strong CYP3A4 inhibitors. Limit simvastatin to 20 mg/day concomitantly. Advise patients on oral contraceptives to use backup methods for 30 days after starting Foundayo and after each dose increase.
• Hepatic impairment: Foundayo is not recommended in severe hepatic impairment (Child-Pugh Class C). No dose adjustment needed for mild or moderate impairment. No adjustment for renal impairment.
• Missed doses: If 7 or more consecutive doses are missed, restart at a lower dose to reduce GI adverse reaction risk.
• GI adverse reactions: Nausea, constipation, diarrhea, and vomiting are the most common reasons for discontinuation. Slow dose escalation (≥30 days at each level) is designed to mitigate this but some patients will still experience GI symptoms, particularly in the early titration phase.

How medfinder Can Help Your Patients

medfinder is a paid service that calls pharmacies on behalf of patients to find which ones have a specific medication in stock. For patients who've been prescribed Foundayo but are struggling with local pharmacy availability, directing them to medfinder.com/providers can help them locate a pharmacy near them without spending hours on the phone. This can reduce patient frustration calls to your office and improve treatment initiation rates.

When to Consider an Alternative to Foundayo

If a patient requires immediate treatment initiation and Foundayo isn't available, consider whether Zepbound (tirzepatide) or Wegovy (semaglutide) is covered by their insurance and available locally. Injectable GLP-1s have more established supply chains. See our detailed Foundayo alternatives guide for clinical comparison details.

Summary for Providers

Foundayo is a genuine advance in obesity pharmacotherapy — the first no-restriction oral GLP-1 for weight management. Its launch-period availability challenges are real but temporary. Proactive patient counseling about LillyDirect, insurance prior auth timelines, and services like medfinder will help your patients access the treatment they need with less friction.